Dr. Michael Rottmann PhD
Roche Diagnostics GmbH
Director Assay Development
Indication: Thyroid, Sepsis, RA, Growth
Centralized and Point of Care solutions
Michael Rottmann is Director of Roche Diagnostics Research and Development for Immunoassays in the Indication: Thyroid, Sepsis, RA, Growth, with 25 years expertise in immunoassay development with FDA registration, CE marking and laboratory management. He is actively involved in transferring diagnostic products to the new EU IVDR regulation. In his indication he has a wide range of international customer contacts for R&D topics. Based on this exchange he can bring the customer needs into the development process for immunoassays and analyzer platforms. He also has 5 years of experience in establishing project management tools in diagnostics. Due to his long experience in industry and serving as a Roche representative in a long tenure with IFCC the networking with other corporate members is well established.
Mr. Rottmann is a Corporate Member in the Scientific Division Executive Committee (SD) and a Corresponding Member in the Task force of Corporate Members (TF-CM) since January 2020.
He is a Consultant in the IFCC Committee Standardization of Tests (C-STFT). He attends the team from scratch on.
He is a Member in the IFCC working group Growth Hormone (WG-GH); Member in the IFCC Committee Harmonization of Autoantibody tests (C-HAT); Member in the IFCC working group Standardization of Procalcitonin assays (WG-PCT).
He is a Consultant in the EMD Committee Proficiency Testing (C-PT).